Spots Global Cancer Trial Database for gastric neoplasms
Every month we try and update this database with for gastric neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST) | NCT02488746 | Gastric Neoplas... Gastrointestina... | GERDX(TM) | 18 Years - | Kliniken Ludwigsburg-Bietigheim gGmbH | |
| CDSS-assisted UGI Endoscopy vs. Routine Screening Endoscopy | NCT05452473 | Healthy Individ... | CDSS-assisted u... no intervention | 20 Years - | Chuncheon Sacred Heart Hospital | |
| Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm | NCT02005809 | Gastric Neoplas... | second look end... | 20 Years - 90 Years | Kosin University Gospel Hospital | |
| Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | NCT01915225 | Colorectal Neop... Gastric Neoplas... Cholangiocarcin... Bile Duct Cance... Pancreas Cancer | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | NCT01166490 | Gastric Neoplas... Pancreatic Neop... | ASG-5ME | 18 Years - | Seagen Inc. | |
| A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | NCT01166490 | Gastric Neoplas... Pancreatic Neop... | ASG-5ME | 18 Years - | Seagen Inc. | |
| Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome | NCT03648879 | Gastric Cancer Gastric Neoplas... | Endoscope+Cellv... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | NCT02942329 | Gastric Cancer Hepatocellular ... | apatinib SHR-1210 | 18 Years - 70 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT05111444 | Gastric Neoplas... Gastroesophagea... | Camrelizumab Pyrotinib Capecitabine Oxaliplatin Paclitaxel S-1 | 18 Years - 75 Years | Fudan University | |
| Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | NCT02942329 | Gastric Cancer Hepatocellular ... | apatinib SHR-1210 | 18 Years - 70 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | NCT03615326 | Gastric Neoplas... Gastroesophagea... | Pembrolizumab Placebo Cisplatin 5-FU Oxaliplatin Capecitabine S-1 Trastuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy | NCT01839773 | Stage IV Gastri... | Paclitaxel Paclitaxel | 20 Years - | Daehwa Pharmaceutical Co., Ltd. | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer | NCT04180761 | Gastric Neoplas... | intraoperative ... | 18 Years - | University Hospital Tuebingen | |
| Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | NCT01915225 | Colorectal Neop... Gastric Neoplas... Cholangiocarcin... Bile Duct Cance... Pancreas Cancer | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT05111444 | Gastric Neoplas... Gastroesophagea... | Camrelizumab Pyrotinib Capecitabine Oxaliplatin Paclitaxel S-1 | 18 Years - 75 Years | Fudan University | |
| Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | NCT01915225 | Colorectal Neop... Gastric Neoplas... Cholangiocarcin... Bile Duct Cance... Pancreas Cancer | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction | NCT00080002 | Cancer of Stoma... Gastroesophagea... | Pegamotecan | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies | NCT04949737 | Stomach Neoplas... Gastric Neoplas... Helicobacter Py... | Helicobacter Py... | 18 Years - | University Hospital Center of Martinique | |
| CDSS-assisted UGI Endoscopy vs. Routine Screening Endoscopy | NCT05452473 | Healthy Individ... | CDSS-assisted u... no intervention | 20 Years - | Chuncheon Sacred Heart Hospital | |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | NCT01576380 | Adenocarcinoma,... Linitis Plastic... Stomach Neoplas... Stomach Disease... Neoplasms by Si... Neoplasms | TKI258 | 20 Years - | Novartis | |
| A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 | NCT01614522 | Stomach Neoplas... Cancer of Stoma... Cancer of the S... Gastric Cancer Gastric Neoplas... | ASLAN001 | 21 Years - | ASLAN Pharmaceuticals | |
| Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies | NCT04949737 | Stomach Neoplas... Gastric Neoplas... Helicobacter Py... | Helicobacter Py... | 18 Years - | University Hospital Center of Martinique | |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) | NCT03019588 | Gastric Neoplas... Gastroesophagea... | Pembrolizumab Paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer | NCT04180761 | Gastric Neoplas... | intraoperative ... | 18 Years - | University Hospital Tuebingen | |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | NCT05152147 | Gastric Neoplas... Gastroesophagea... Esophageal Aden... | Zanidatamab Tislelizumab Trastuzumab Capecitabine Oxaliplatin Cisplatin 5-Fluorouracil | 18 Years - | Jazz Pharmaceuticals | |
| A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 | NCT01614522 | Stomach Neoplas... Cancer of Stoma... Cancer of the S... Gastric Cancer Gastric Neoplas... | ASLAN001 | 21 Years - | ASLAN Pharmaceuticals | |
| Chromogranin A as Blood Marker in Cancer Patients | NCT03817866 | Gastric Neoplas... Pancreatic Neop... Small Intestina... Colorectal Neop... | BRAHMS CgA II K... | 18 Years - 85 Years | Brahms AG |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
